Published
September 21, 2021
SMSbiotech Successfully Completes First Test of a Series of Animal Studies for COPD Treatment
SAN DIEGO, CA, September 17, 2021 – SMSbiotech is very excited to launch its new series of animal studies in cooperation with a partnering CRO. The first test of this series has concluded and indicates the strong safety pattern associated with the direct application of Small Mobile Stem (SMS) cells to the lungs.
Abdulkader Rahmo, PhD, CSO for SMSbiotech states “Having had the exciting results regarding SMS cells interacting with several lung cells makes us eager to finalize all animal safety testing. This is a very promising start”.
The company intends to continue the GLP safety studies required for obtaining FDA approval to launch human trials for the treatment of lung damage in COPD patients.
Resources
No items found.
This is some text inside of a div block.
